Fig. 2: KRAS mutational spectrum on the study.
From: Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial
Frequency of specific KRAS mutations of tumours (n = 249) included together with KRAS WT PDAC proportion (n = 19).
